Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Petco Health & Wellness Co Inc (Symbol: WOOF), where a total of 26,358 contracts have ...
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following ...
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...
Citius Pharmaceuticals is a late-stage biotech with a drug to treat lymphoma, but their cash runway is not long enough for FDA approval. Their flagship drug, Lymphir, has shown promising results in a ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI – Research Report), Tempest Therapeutics (TPST – Research Report) and Citius ...
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Citius Pharmaceuticals (CTXR – Research Report) yesterday and set a price target of $4.00. The company’s shares opened today at $1.56.
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results